The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts-Reference-Cited by-同舟云学术

The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts

Published:2016-11-10 Issue:6 Volume:58 Page:1481-1487
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Scherber Robyn Marie¹²,Geyer Holly Lynn³,Dueck Amylou C.⁴,Kosiorek Heidi E.⁴,Finazzi Guido⁵,Cavazzina Riccardo⁶,Masciulli Arianna⁷,Scarano Marco⁷,Vannucchi Alessandro M.⁸,Mesa Ruben A.¹,Barbui Tiziano⁵

Affiliation:

1. Department of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA;

2. Department of Hematology and Oncology, Oregon Health and Science University, Portland, OR, USA;

3. Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA;

4. Department of Biostatistics, Mayo Clinic, Scottsdale, AZ, USA;

5. Unit of Hematology, Ospedale Papa Giovanni XXIII, Foundation for Research (FROM), Bergamo, Italy;

6. Consorzio Mario Negri Sud, Santa Maria Imbaro (CH), Italy;

7. Istituto Mario Negri Sud, S. Maria Imbaro, Italy;

8. Section of Hematology, University of Florence, Florence, Italy

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1246733

Reference18 articles.

1. New mutations and pathogenesis of myeloproliferative neoplasms

2. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: Pathogenetic mechanisms and prevention

3. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)

4. Polycythemia vera: myths, mechanisms, and management

5. How I treat polycythemia vera

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera;Clinical Lymphoma Myeloma and Leukemia;2023-11

2. The JAK2_V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden;eJHaem;2023-10-31

3. Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera;Journal of Comparative Effectiveness Research;2023-09

4. Novel therapeutic strategies for essential thrombocythemia/polycythemia vera;Blood Research;2023-04-30

5. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera;Annals of Hematology;2022-08-30